Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph A Odin

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Gastroenterology|January 22, 2019
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver InjuryElizabeth T Cirulli, Paola Nicoletti, Karen Abramson, et al.
World Journal of Virology|November 18, 2017
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial resultsKian Bichoupan, Neeta Tandon, James F Crismale, et al.
Nature Genetics|July 20, 2010
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosisGideon M Hirschfield, Xiangdong Liu, Younghun Han, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Nature Genetics|December 20, 2016
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel diseaseSun-Gou Ji, Brian D Juran, Sören Mucha, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Gastroenterology|January 22, 2019
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver InjuryElizabeth T Cirulli, Paola Nicoletti, Karen Abramson, et al.
World Journal of Virology|November 18, 2017
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial resultsKian Bichoupan, Neeta Tandon, James F Crismale, et al.
Nature Genetics|July 20, 2010
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosisGideon M Hirschfield, Xiangdong Liu, Younghun Han, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Nature Genetics|December 20, 2016
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel diseaseSun-Gou Ji, Brian D Juran, Sören Mucha, et al.
Pageof 5